Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Salesforce Inc (CRM) Price & Performance

ACADIA Pharmaceuticals (ACAD) trades at $29.47, up 0.26% with strong technical momentum and bullish moving average signals. The company reported robust Q2 2026 earnings of $0.18 per share, beating estimates by 164%, driven by strong Daybue and Nuplazid sales. Revenue reached $1.07 billion in 2025 with impressive net income margins of 33.42%. Recent FDA Fast Track designation for remlifanserin in Alzheimer's disease psychosis adds to positive catalysts.

ACAD presents compelling growth potential with 70% analyst buy ratings and a $33.89 consensus price target implying 15% upside. Strong revenue growth trajectory and expanding profitability support bullish case, though elevated EV/EBITDA of 42.55 and recent RSI overbought signals warrant caution. Key risk remains clinical trial outcomes for pipeline assets.

Salesforce (CRM) trades at $197.47, showing minimal daily movement (-0.02%) but facing significant year-to-date pressure amid a broader software sector sell-off. The company maintains strong fundamentals with consistent earnings beats, robust profitability (77.6% gross margin, 18.7% net margin), and healthy cash flow generation. Recent news highlights AI-driven growth potential through Agentforce and Data 360 products, though competitive pressures and macroeconomic concerns weigh on sentiment.

The stock presents a compelling valuation opportunity with a 22.4 P/E ratio trading below the analyst consensus target of $231.91 (17% upside). Strong earnings momentum, AI monetization progress, and improving cash flows support long-term growth, but investors face near-term volatility from sector-wide AI disruption fears and competitive threats. Wall Street remains overwhelmingly bullish (76% buy ratings) despite recent price weakness.